Illumina Inc.ILMN

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · illumina.com

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis globally. Its platforms power applications in genomic research, drug development, oncology testing, reproductive health screening, and population genomics programs. The company serves genomic research centers, academic institutions, pharmaceutical and biotechnology companies, clinical laboratories, and consumer genomics companies worldwide.

Key ratios

Operating cash flow growth

-5.1%TTM

2025 28.9%2024 75.1%2023 21.9%

EPS growth

-32.1%TTM

FCF / Sales

20.7%TTM

2025 21.4%2024 16.2%2023 6.3%

Net margin

18.3%TTM

2025 19.6%2024 -28.0%2023 -25.8%

ROA

8.7%TTM

2025 8.4%2024 3.1%2023 -0.4%

ROE

33.4%TTM

2025 33.4%2024 -30.1%2023 -18.8%

Revenue growth

4.9%TTM

2025 -0.7%2024 -2.9%2023 -1.8%

Recent news

Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors 2026-06-23 · PR Newswire Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution 2026-06-08 · PR Newswire

Track ILMN in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer